VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

Exclusion Criteria

• •History or other clinical evidence of significant or unstable cardiac disease
• •Evidence of hepatic decompensation
• •Diagnosed or suspected hepatocellular carcinoma
• •Any other cause of significant liver disease in addition to hepatitis C, which may include but is not limited to malignancy with hepatic involvement, hepatitis B, drug-or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, nonalcoholic steatohepatitis, or primary biliary cirrhosis
• •History of organ transplant, with the exception of corneal transplants and skin grafts